IP Library Granted Patent US 9,790,533
Granted Patent B2
US 9,790,533 · App. 15/425,056 · Granted Oct 17, 2017

Methods of preventing and removing trisulfide bonds

Inventors: Rashmi Rohit Kshirsagar (Ashland, MA); Alan Gilbert (Cambridge, MA)
Assignee: Biogen MA Inc.
C12P21/00A61K39/39591C07K1/1133C07K16/00C12N5/0018A61K2039/505C07K2317/40C07K2317/41C07K2317/94C12N2500/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,790,533
App. No.
15/425,056
Granted
Oct 17, 2017
Kind
B2
Abstract

The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.

Claims (10)

1. A cell culture for reducing the formation of trisulfide bonds in a protein comprising a culture medium which comprises an effective amount of an inhibitor of cysteine degradation selected from methyl pyruvate, ethyl pyruvate, glyceraldehyde, and glyoxylic acid.

2. The cell culture of claim 1 , further comprising a cell which expresses said protein.

3. The cell culture of claim 2 , wherein said cell is a mammalian cell.

4. The cell culture of claim 3 , wherein said mammalian cell is a CHO (Chinese Hamster Ovary) (including CHO-K1, CHO DG44, and CHO DUXB11), VERO, HeLa, (human cervical carcinoma), CVI (monkey kidney line), (including COS and COS-7), BHK (baby hamster kidney), MDCK, C127, PC12, HEK-293 (including HEK-293T and HEK-293E), PER C6, NSO, WI38, R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HAK (hamster kidney line), SP2/0 (mouse myeloma), P3x63-Ag3.653 (mouse myeloma), BFA-1c1BPT (bovine endothelial cells), RAJI (human lymphocyte) or 293 (human kidney) cell.

5. The cell culture of claim 1 , wherein the ratio of the inhibitor to cysteine is about 5:1 to 1:10.

6. The cell culture of claim 1 , wherein said inhibitor is at a concentration of between about 50 μM to about 500 mM.

7. The cell culture of claim 6 , wherein said inhibitor is at a concentration of between about 100 μM to about 100 mM.

8. The cell culture of claim 7 , wherein said inhibitor is at a concentration of between about 1 mM and 100 mM.

9. The cell culture of claim 8 , wherein said inhibitor is at a concentration of between about 5 mM to about 50 mM.

10. The cell culture of claim 1 , wherein said culture medium comprises IMDM or DMEM.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: KSHIRSAGAR, RASHMI ROHIT; GILBERT, ALAN
To: BIOGEN IDEC MA INC.
Reel/Frame 042406/0489 →
CHANGE OF NAME Recorded May 17, 2017
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 042483/0244 →
Continuity (4)
Division 14117554
Provisional Application 61617529 · Mar 29, 2012
Provisional Application 61485973 · May 13, 2011
Related Publication 20170247655A1 · Aug 31, 2017